Fortress Biotech, Inc. (FBIO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1154405,
    "name": "Fortress Biotech, Inc.",
    "stock_name": "Fortress Biotech, Inc.",
    "full_name": "Fortress Biotech, Inc.",
    "name_url": "stocks-analysis/fortress-biotech-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.75",
    "chg": 0.18,
    "chgp": "7.0%",
    "dir": 1,
    "prev_price": "2.57",
    "mcapval": "107.12",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US34960Q3074",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.18 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/fortress-biotech-inc-1154405-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Fortress Biotech Hits New 52-Week High of $4.11, Up 104%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/fortress-biotech-hits-new-52-week-high-of-411-up-104-3559327",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/FortressBiotech_priceRelatedfactors_3559327.png",
        "date": "2025-09-23 15:37:51",
        "description": "Fortress Biotech, Inc. achieved a new 52-week high of USD 4.11 on September 22, 2025, reflecting a significant one-year performance increase. With a market capitalization of USD 107 million, the company operates in a competitive sector, showcasing notable financial metrics despite challenges in profitability and debt management."
      },
      {
        "title": "Is Fortress Biotech, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-fortress-biotech-inc-technically-bullish-or-bearish-3545962",
        "imagepath": "",
        "date": "2025-09-20 19:22:08",
        "description": "As of 11 August 2025, the technical trend for Fortress Biotech, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages also indicate a bullish stance. However, the monthly RSI is bearish, which presents a mixed signal. The Bollinger Bands show a bullish trend on a monthly basis and mildly bullish on a weekly basis. The KST is bullish weekly and mildly bullish monthly, while the Dow Theory indicates a mildly bullish trend monthly with no trend weekly. \n\nIn terms of performance, the stock has significantly outperformed the S&P 500 over the past month (58.22% vs. 2.33%) and year (85.42% vs. 17.14%), but has underperformed over the longer three and five-year periods. Overall, the current technical stance is bullish, with strength primarily driven by the moving averages and MACD indicators...."
      },
      {
        "title": "Is Fortress Biotech, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-fortress-biotech-inc-overvalued-or-undervalued-3542613",
        "imagepath": "",
        "date": "2025-09-20 17:57:26",
        "description": "As of 10 May 2016, the valuation grade for Fortress Biotech, Inc. moved from does not qualify to risky. The company is considered overvalued given its negative financial metrics and poor performance compared to peers. The Price to Book Value stands at 2.66, while the EV to EBITDA is -0.31, indicating significant valuation challenges. Additionally, the company's Return on Equity (ROE) is an alarming -482.55%, further underscoring its financial instability.\n\nIn comparison to peers, Fortress Biotech's EV to EBITDA ratio is better than Assembly Biosciences, Inc. at -6.6467 and Sol-Gel Technologies Ltd. at -11.1084, but still reflects a concerning trend. The stock has shown a strong return of 85.42% over the past year, significantly outperforming the S&P 500's 17.14% return, although its longer-term performance remains troubling with a 5-year return of -95.03%...."
      }
    ],
    "total": 8,
    "sid": "1154405",
    "stock_news_url": "https://www.marketsmojo.com/news/fortress-biotech-inc-1154405"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Fortress Biotech Hits New 52-Week High of $4.11, Up 104%

2025-09-23 15:37:51

Fortress Biotech, Inc. achieved a new 52-week high of USD 4.11 on September 22, 2025, reflecting a significant one-year performance increase. With a market capitalization of USD 107 million, the company operates in a competitive sector, showcasing notable financial metrics despite challenges in profitability and debt management.

Is Fortress Biotech, Inc. technically bullish or bearish?

2025-09-20 19:22:08

As of 11 August 2025, the technical trend for Fortress Biotech, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages also indicate a bullish stance. However, the monthly RSI is bearish, which presents a mixed signal. The Bollinger Bands show a bullish trend on a monthly basis and mildly bullish on a weekly basis. The KST is bullish weekly and mildly bullish monthly, while the Dow Theory indicates a mildly bullish trend monthly with no trend weekly. In terms of performance, the stock has significantly outperformed the S&P 500 over the past month (58.22% vs. 2.33%) and year (85.42% vs. 17.14%), but has underperformed over the longer three and five-year periods. Overall, the current technical stance is bullish, with strength primarily driven by the moving averages and MACD indicators....

Is Fortress Biotech, Inc. overvalued or undervalued?

2025-09-20 17:57:26

As of 10 May 2016, the valuation grade for Fortress Biotech, Inc. moved from does not qualify to risky. The company is considered overvalued given its negative financial metrics and poor performance compared to peers. The Price to Book Value stands at 2.66, while the EV to EBITDA is -0.31, indicating significant valuation challenges. Additionally, the company's Return on Equity (ROE) is an alarming -482.55%, further underscoring its financial instability. In comparison to peers, Fortress Biotech's EV to EBITDA ratio is better than Assembly Biosciences, Inc. at -6.6467 and Sol-Gel Technologies Ltd. at -11.1084, but still reflects a concerning trend. The stock has shown a strong return of 85.42% over the past year, significantly outperforming the S&P 500's 17.14% return, although its longer-term performance remains troubling with a 5-year return of -95.03%....

View All News